Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4

Current HIV Research

Volumn 6, Issue 1, 2008, Pages 34-42

  Endo, Masafumi ^a   Inatsu, Asako ^a   Hashimoto, Koji ^a   Takamune, Nobutoki ^a   Shoji, Shozo ^a   Misumi, Shogo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Breast cancer; CXCR4; HIV 1 envelope protein

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; PERTUSSIS TOXIN; PLERIXAFOR; POLYCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL SURFACE; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; NONHUMAN; PHENOTYPIC VARIATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TIME; VIRUS ISOLATION; VIRUS RESISTANCE; ARTICLE; BREAST TUMOR; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

ANTIGENS, CD4; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE PRODUCTS, ENV; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; RECEPTORS, CXCR4;

EID: 40449120292     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783571991     Document Type: Review

References (41)

1. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617-622.
2. McCune JM. The dynamics of CD4+ T-cell depletion in HIV dis ease. Nature 2001; 410: 974-979.
3. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001; 37:1316-1319.
4. Spano JP, Atlan D, Breau JI, et al. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part I: Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Eur J Intern Med 2002; 13: 170-179.
5. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833-1839.
6. Phelps RM, Smith DK, Heilig CM, et al. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94: 753-757.
7. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32: 527-533.
8. Remick SC. Non-AIDS-defining cancers. Hematol Oncol Clin North Am 1996; 10: 1203-1213.
9. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16: 1155-1161.
10. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 3447-3453.
11. Amir H, Kaaya EE, Kwesigabo G, et al. Breast cancer before and during the AIDS epidemic in women and men: a study of Tanzanian Cancer Registry Data 1968 to 1996. J Natl Med Assoc 2000; 92: 301-305.
12. Pantanowitz L, Dezube BJ. Reasons for a deficit of breast cancer among HIV-infected patients. J Clin Oncol 2004; 22: 1347-1348.
13. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999; 21: 107-113.
14. Schreier LE, Berg GA, Basilio FM, et al. Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 1999; 47: 681-690.
15. Krown SE. Breast cancer in the setting of HIV infection: cause for concern? Cancer Invest 2002; 20(4): 590-592.
16. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9: 551-562.
17. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
18. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: 621-628.
19. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-1265.
20. Weissman D, Rabin RL, Arthos J, et al. Macrophage-tropic HIV an SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 1997; 389: 981-985.
21. Algeciras-Schimnich A, Vlahakis SR, Villasis-Keever A, et al. CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4 T cells. AIDS 2002; 16: 1467-1478.
22. Ahr B, Robert-Hebmann V, Devaux C, et al. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004; 1:12.
23. Berndt C, Mopps B, Angermuller S, et al. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc Natl Acad Sci USA 1998; 95: 12556-12561.
24. Kreisberg JF, Kwa D, Schramm B, et al. Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol 2001; 75; 8842-8847.
25. Holm GH, Zhang C, Gorry PP, et al. Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/ receptor affinity and coreceptor binding site exposure. J Virol 2004; 78: 4541-4551.
26. Herbein G, Mahlknecht U, Batliwalla F, et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998; 395: 189-194.
27. Penn ML, Grivel JC, Schramm B, et al. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci USA 1999; 96: 663-668.
28. Jekle A, Schramm B, Jayakumar P, et al. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol 2002; 76: 6966-6973.
29. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
30. Kato M, Kitayama J, Kazama S, et al. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003; 5: R144-150.
31. Misumi S, Endo M, Mukai R, et al. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. J Biol Chem 2003; 278: 32335-32343.
32. Remick SC, Harper GR, Abdullah MA, et al. Metastatic breast cancer in a young patient seropositive for human immunodeficiency virus. J Natl Cancer Inst 1991; 83: 447-448.
33. Samuelsson A, Brostrom C, van Dijk N, et al. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection - correlation with clinical progression, viral load, and loss of humoral immunity. Virology 1997; 238: 180-188.
34. Vlahakis SR, Villasis-Keever A, Gomez TS, et al. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 2003; 188: 1455-1460.
35. Baribaud F, Edwards TG, Sharron M, et al. Antigenically distinct conformations of CXCR4. J Virol 2001; 75: 8957-8967.
36. Olshevsky U, Helseth E, Furman C, et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990; 64: 5701-5707.
37. Gallagher B, Wang Z, Schymura MJ, et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154: 544-556.
38. Biggar RJ, Kirby KA, Atkinson J, et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36: 861-868.
39. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-1745.
40. Pantanowitz L, Dezube BJ. Breast cancer in women with HIV/AIDS. JAMA 2001; 285: 3090-3091.
41. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-179.